Evaluation of rhBMP-2 and natural latex as potential osteogenic proteins in critical size defects by histomorphometric methods.
This in vivo study evaluated the osteogenic potential of two proteins, recombinant human bone morphogenetic protein-2 (rhBMP-2) and a protein extracted from natural latex (Hevea brasiliensis, P-1), and compared their effects on bone defects when combined with a carrier or a collagen gelatin. Eighty-four (84) Wistar rats were divided into two groups, with and without the use of collagen gelatin, and each of these were divided into six treatment groups of seven animals each. The treatment groups were: (1) 5 microg of pure rhBMP-2; (2) 5 microg of rhBMP-2/monoolein gel; (3) pure monoolein gel; (4) 5 microg of pure P-1; (5) 5 microg of P-1/monoolein gel; (6) critical bone defect control. The animals were anesthetized and a 6 mm diameter critical bone defect was made in the left posterior region of the parietal bone. Animals were submitted to intracardiac perfusion after 4 weeks and the calvaria tissue was removed for histomorphometric analysis. In this experimental study, it was concluded that rhBMP-2 allowed greater new bone formation than P-1 protein and this process was more effective when the bone defect was covered with collagen gelatin (P < 0.05).
Issa
João Paulo Mardegan
JP
Department of Morphology, Stomathology, and Physiology, School of Dentistry at Ribeirao Preto, University of Sao Paulo, Brazil. jpmissa@forp.usp.br
Defino
Helton Luiz Aparecido
HL
Netto
Joaquim Coutinho
JC
Volpon
José Batista
JB
Regalo
Simone Cecílio Hallak
SC
Iyomasa
Mamie Mizusaki
MM
Siéssere
Selma
S
Tiossi
Rodrigo
R
D000818:Animals; D001847:Bone Diseases / Q000188:drug therapy*; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology* / Q000627:therapeutic use; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D001842:Bone and Bones / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D050723:Fractures, Bone / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D028482:Hevea / Q000737:chemistry; D006801:Humans; D007840:Latex / Q000737:chemistry; D008297:Male; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use; D010940:Plant Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D007840:Latex; D010936:Plant Extracts; D010940:Plant Proteins; D011994:Recombinant Proteins